These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18138747)

  • 1. Treatment of adults for epilepsy; toxic effect of 3-methyl 5-5-phenylethylhydantoin.
    BAILEY AA; WORDEN RE
    Proc Staff Meet Mayo Clin; 1949 Sep; 24(19):483-6. PubMed ID: 18138747
    [No Abstract]   [Full Text] [Related]  

  • 2. [3-Methyl-5, 5-phenylethylhydantoin therapy of epilepsy].
    DONATI A; BERNARDI L
    Rass Studi Psichiatr; 1952; 41(6):1171-92. PubMed ID: 13047632
    [No Abstract]   [Full Text] [Related]  

  • 3. [The value of 3-methyl 5.5. phenylethylhydantoin in therapy of epilepsy].
    HOLTZER PA
    Geneeskd Gids; 1952 May; 30(9):181-7. PubMed ID: 14955069
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neural and endocrine complications in the treatment of epilepsy with hydantoins].
    VERGER P
    J Med Bord; 1952 May; 129(5):425-6. PubMed ID: 14938802
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lymph node manifestations during treatments with 3-methyl-5, 5-phenylethylhydantoin].
    OLMER J; PAILLAS J; ROGER J; MURATORE R; BADIER
    Bull Mem Soc Med Hop Paris; 1952 Jun 20-27; 68(22-23):839-41. PubMed ID: 12978867
    [No Abstract]   [Full Text] [Related]  

  • 6. [The injurious effect of hydantoins on bone marrow with reference to a fatal panmyelophthisis following sacerno (3-methyl 5, 5-phenylethylhydantoin) therapy].
    BAN A; BERCZELLER I
    Orv Hetil; 1952 Apr; 93(16):480-4. PubMed ID: 13003265
    [No Abstract]   [Full Text] [Related]  

  • 7. [General review of the toxic side-effects caused by hydantoin derivatives used in epilepsy].
    FACCHETTI G
    Cervello G Nevrol; 1962 Mar; 38():147-60. PubMed ID: 13891254
    [No Abstract]   [Full Text] [Related]  

  • 8. [Apropos of neurological complications of the treatment of epilepsy by hydantoins].
    ROGER J; SOULAYROL R
    Rev Neurol (Paris); 1959 Jun; 100():783-5. PubMed ID: 14438340
    [No Abstract]   [Full Text] [Related]  

  • 9. [Case of agranulocytosis occurring during mesantoin therapy of epilepsy].
    RIGOTTI S
    Riv Neurol; 1951; 21(6):532-8. PubMed ID: 14942315
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hemopoietic complications of hydantoin therapy of epilepsy].
    MANNHEIMER E; PAKESCH F; REIMER EE; VETTER H
    Med Klin; 1952 Oct; 47(42):1397-1401. PubMed ID: 13001915
    [No Abstract]   [Full Text] [Related]  

  • 11. Dilantin toxicity. A clinical and electroence-phalographic study.
    ROSEMAN E
    Neurology; 1961 Oct; 11():912-21. PubMed ID: 13743310
    [No Abstract]   [Full Text] [Related]  

  • 12. Occurrence of skin pigmentation during mesantoin therapy.
    HUNTER H; JENKINS D
    J Am Med Assoc; 1951 Oct; 147(8):744-8. PubMed ID: 14873548
    [No Abstract]   [Full Text] [Related]  

  • 13. [Granulocytopenic syndromes in mesantoin therapy].
    BELSASSO M; BONIVENTO M
    Minerva Med; 1952 Oct; 43(79):558-62. PubMed ID: 13013023
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatal hepatic necrosis occurring during therapy with phethenylate sodium.
    BUTSCHER WC; GALLAGER HS
    J Am Med Assoc; 1952 Feb; 148(7):535-6. PubMed ID: 14888521
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical and experimental data on goiters with hypothyroidism induced by dimethyldithiohydantoin].
    GUINET P; BERGER M
    Ann Endocrinol (Paris); 1951; 12(4):544-8. PubMed ID: 14878226
    [No Abstract]   [Full Text] [Related]  

  • 16. Aplasia of the bone marrow during mesantoin therapy; report of a fatal case.
    WITKIND E; WAID ME
    J Am Med Assoc; 1951 Oct; 147(8):757-9. PubMed ID: 14873554
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lymphadenopathy following triantoin in audiogenic epilepsy].
    POKORNA M; ROSSLER M
    Cesk Pediatr; 1962 Apr; 17():354-8. PubMed ID: 14487454
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute hepatic necrosis with death occurring during phethenylate sodium therapy; report of two cases.
    PRYLES CV; BURNETT JM; LIVINGSTON S
    J Am Med Assoc; 1952 Feb; 148(7):536-8. PubMed ID: 14888522
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lupus erythematosus or a disease simulating lupus erythematosus developing following triantoin therapy].
    BLEHOVA B; DANESOVA J; MILUNICOVA A; STOLZ J
    Cesk Pediatr; 1959 Jul; 14():654-7. PubMed ID: 13801442
    [No Abstract]   [Full Text] [Related]  

  • 20. A NEW ANTICONVULSANT, 1-METHYL-5:5-PHENYLETHYLHYDANTOIN. ITS USE IN PEDIATRICS.
    OETTINGER L; NEKONISHI H
    Dev Med Child Neurol; 1965 Apr; 7():189-95. PubMed ID: 14317536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.